Physician profile
Mohammad-Ehsan Owrangi
NPI 1023660677
$2,618.60
in general payments reported to CMS, 2019-2025
24 companies · $1,944 in 2025
The $1,944 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $118 · 2024: $556 · 2025: $1,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $300.06 | 2024-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $297.27 | 2024-2025 | |
| Novo Nordisk INC | $284.69 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amneal Pharmaceuticals LLC | $216.53 | 2024-2025 | Unithroid |
| Beta Bionics, INC. | $179.13 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic, INC. | $166.31 | 2024-2025 | Minimed 780g |
| Lilly USA, LLC | $164.68 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $156.93 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $99.54 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $95.46 | 2023-2025 | Tepezza, Enbrel, Tavneos |
| Recordati_rare_diseases_inc. | $76.11 | 2023-2025 | Isturisa, Signifor Lar |
| Mannkind Corporation | $73.99 | 2025 | |
| Corcept Therapeutics | $69.98 | 2025 | Korlym |
| Ibsa Pharma INC. | $68.18 | 2025 | Tirosint, Licart, Flector |
| Abbott Laboratories | $60.66 | 2025 | Freestyle Libre 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $59.71 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.59 | 2025 | Jardiance |
| Abbvie INC. | $45.30 | 2024-2025 | |
| Rgh Enterprises LLC | $43.19 | 2025 | |
| Novartis Pharmaceuticals Corporation | $28.29 | 2025 | |
| Ascendis Pharma Endocrinology INC | $21.61 | 2025 | Yorvipath |
| Chiesi USA, INC. | $21.28 | 2025 | Mycapssa |
| Glaxosmithkline, LLC. | $19.75 | 2025 | Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $18.36 | 2025 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad-Ehsan Owrangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.